Cogent Biosciences (COGT) Capital Expenditures (2017 - 2026)

Cogent Biosciences (COGT) has reported Capital Expenditures for 9 consecutive years, with $449000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 17.92% year-over-year to $449000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 38.67% YoY), while the FY2025 annual figure was $1.6 million, up 171.2% from the prior year.
• Capital Expenditures retreated to $449000.0 in Q1 2026 per COGT's latest filing, from $811000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.3 million in Q3 2022 and bottomed at $65000.0 in Q3 2025.
• Historically, Capital Expenditures has averaged $719705.9 across 5 years, with a median of $441000.0 in 2022.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 96.35% — and 2025, when it surged 981.33%.
• Cogent Biosciences' Capital Expenditures stood at $2.0 million in 2022, then plunged by 83.99% to $315000.0 in 2023, then tumbled by 76.19% to $75000.0 in 2024, then soared by 981.33% to $811000.0 in 2025, then slumped by 44.64% to $449000.0 in 2026.
• Business Quant data shows COGT's Capital Expenditures at $449000.0 in Q1 2026, $811000.0 in Q4 2025, and $65000.0 in Q3 2025.